ARTICLE | Emerging Company Profile
GeneCentric: Cancer sign-off
GeneCentric is developing cancer diagnostics based on gene signatures
February 11, 2013 8:00 AM UTC
GeneCentric Diagnostics Inc. was founded to translate gene sequences into out-licensable assets for partners to market as laboratory-developed tests. The first product based on a GeneCentric assay - a test to help subtype non-small cell lung cancer and guide therapy - was launched by Laboratory Corp. of America Holdings last month.
President and CEO Myla Lai-Goldman said GeneCentric's first programs are based on two genetic signatures identified by University of North Carolina researchers and company co-founders David Neil Hayes and Charles Perou. GeneCentric exclusively licensed the IP last year...